[COVID-19: Still a place for tocilizumab?]

Richier, Q; Plaçais, L; Lacombe, K; Hermine, O

[COVID-19: Still a place for tocilizumab?] / COVID-19 : encore une place pour le tocilizumab ?

Richier, Q; Plaçais, L; Lacombe, K; Hermine, O.

Richier Q; Service de maladies infectieuses, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France. Electronic address: quentin.richier@hotmail.fr.
Plaçais L; Service d'hématologie, hôpital Necker, Assistance publique des Hôpitaux de Paris, Paris, France; Sorbonne université, Paris, France.
Lacombe K; Service de maladies infectieuses, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris, Paris, France; Sorbonne université, Paris, France.
Hermine O; Université de Paris, Paris, France; Service d'hématologie, hôpital Necker, Assistance publique des Hôpitaux de Paris, Paris, France; Inserm U 1163, institut Imagine, Paris, France.

Rev Med Interne ; 42(2): 73-78, 2021 02.

Article in French | MEDLINE | ID: covidwho-1065561

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; COVID-19 Drug Treatment; COVID-19/epidemiology; COVID-19/pathology; Humans; Interleukin-6/physiology; Pandemics; Randomized Controlled Trials as Topic/statistics & numerical data; SARS-CoV-2/drug effects; SARS-CoV-2/physiology; Severity of Illness Index; Treatment Outcome

Keywords

COVID-19; Hyperinflammation; Interleukin-6; Interleukine-6; SARS-COV-2; SARS-CoV-2; Tocilizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: French Journal: Rev Med Interne Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google